摘要
小细胞肺癌(SCLC)主要的特点为生长迅速且早期易发生广泛转移。尽管SCLC对于化疗和放疗敏感,但几乎所有的患者均在治疗后发生复发转移,预后差。免疫检测点抑制剂,尤其程序化细胞死亡受体-1(PD-1)/程序化细胞死亡配体-1(PD-L1)拮抗剂在SCLC的临床前和临床研究中均获得了良好效果,并且能够延长患者生存。免疫检测点疗法作为一种新兴的方法在未来可能会改变SCLC治疗模式。此外,有限的数据显示出PD-L1表达可能成为筛选获益人群一个有效的生物标记物。本文总结PD-L1作为标记物的发展历程,并同时阐述PD-1/PD-L1抑制剂在SCLC治疗中的进展。
SmaU-cell lung cancer（SCLC） is characterized by its rapid growth and early development of widespread metastases. Although patients with SCLC are highly responsive to chemotherapy and radiation therapy, long-term prognosis remains poor, with relapse and disease metastasis occurring in almost all cases. Immune checkpoint blockade, especially blockade of programmed death-1 （PD-1） receptor and its ligand PD-L1, achieved robust responses and improved survival for patients with SCLC in preclinical and clinical studies. The blockade of PD-1/PD-L1 pathway as a novel therapeutic approach may change the treatment paradigm of SCLC in the future. Data on clinical activity by programmed cell death-1 ligand expression in SCLC are not widely available. In addition, limited data indicate that PD-L1 expression may be an ideal biomarker for patient selection. Here, we summarize the brief history of PD-L1 as a biomarker and describe the critical role of PD-1/PD-L1 inhibitors in SCLC.
出处
《临床肿瘤学杂志》
CAS
2017年第3期277-280,共4页
Chinese Clinical Oncology
基金
黑龙江卫生计生委科研课题资助项目(2016-102)
